The development of new tools to quantify the many ways that rare diseases like FCS can affect patients is imperative.
Michael W. Stevenson, RPh, PhD
Advertisement
Articles by Michael W. Stevenson, RPh, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
New Dyslipidemia Guidelines Reveal Significant Gap in LDL-C and LLT Treatment Goals
2
Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2
3
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
4
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
5